Page 694 - 16Neonatal Jaundice_compressed

Appendix J: Excluded studies

Reference Reason for exclusion
Pishva N, Madani A, and Homayoon K. Prophylactic intravenous immunoglobulin in neonatal immune hemolytic jaundice. Prevention study
Iranian Journal of Medical Sciences 2000; 25:(3–4)129.
Poland RL and Odell GB. Physiologic jaundice: the enterohepatic circulation of bilirubin. New England Journal of Medicine Prevention study
1971; 284:(1)1–6.
Ramboer C, Thompson RP, and Williams R. Controlled trials of phenobarbitone therapy of neonatal jaundice. Lancet 1969; Prevention study
1:(7602)966–8.
Ramboer C, Thompson RP, and Williams R. Treatment of neonatal jaundice with phenobarbitone. Gut 1969; 10:(5)414. Conference abstract
Romagnoli C, Polidori G, Foschini M et al. Agar in the management of hyperbilirubinaemia in the premature baby. Archives of Prevention study
Disease in Childhood 1975; 50:(3)202–4.
Rubo J, Wahn V, Hohendahl J et al. Influence of high dosage immuno-globulin therapy on hyperbilirubinemia in rhesus-hemolytic Non-English language paper
disease. A cooperative study. Monatsschrift fur Kinderheilkunde 1996; 144:(5)516–9.
Salle B, Pasquer P, Desebbe C et al. Phenobarbital in prophylaxis of neonatal jaundice. A control trial of two regimens. Helvetica Prevention study
Paediatrica Acta 1977; 32:(3)221–6.
Segni G, Polidori G, and Romagnoli C. Bucolome in prevention of hyperbilirubinaemia in preterm infants. Archives of Disease in Prevention study
Childhood 1977; 52:(7)549–50.
Spinelli SL, Otheguy LE, Larguia MA et al. Postnatal use of high-dose intravenous immunoglobulin therapy in rhesus hemolytic Conference abstract
disease treatment. Journal of Perinatal Medicine 2001; 29:(Suppl 1)683.
Tanyer G, SiklarZ, Dallar Y et al. Multiple dose IVIG treatment in neonatal immune hemolytic jaundice. Journal of Tropical Not an RCT
Pediatrics 2001; 47:(1)50–3.
Todorovic N, Lukic B, and Barjaktarovic N. The effect of phototherapy and phenobarbital on sister-chromatid exchanges in Not an RCT
jaundiced newborns. Archives of Gastroenterohepatology 1993; 12:(3–4)143–4.
Trevett TN, Jr., Dorman K, Lamvu G et al. Antenatal maternal administration of phenobarbital for the prevention of exchange Not an RCT
transfusion in neonates with hemolytic disease of the fetus and newborn. American Journal of Obstetrics and Gynecology 2005;
192:(2)478–82.
Valaes T, Drummond GS, and Kappas A. Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient Five prevention studies
newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics 1998; 101:(5)E1.
Valaes T, Kipouros K, Petmezaki S et al. Effectiveness and safety of prenatal phenobarbital for the prevention of neonatal jaundice. Prevention study
Pediatric Research 1980; 14:(8)947–52.
Valaes T, Petmezaki S, and Doxiadis SA. Effect on neonatal hyperbilirubinemia of phenobarbital during pregnancy or after birth: Prevention study
practical value of the treatment in a population with high risk of unexplained severe neonatal jaundice. Birth defects original
article series 1970; 6:(2)46–54.
Valaes T, Petmezaki S, Henschke C et al. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies Prevention study
with tin-mesoporphyrin. Pediatrics 1994; 93:(1)1–11.
Valdes OS, Maurer HM, Shumway CN et al. Controlled clinical trial of phenobarbital and-or light in reducing neonatal Prevention study
hyperbilirubinemia in a predominantly Negro population. Journal of Pediatrics 1971; 79:(6)1015–7.
Vest M, Signer E, Weisser K et al. A double blind study of the effect of phenobarbitone on neonatal hyperbilirubinaemia and Prevention study
frequency of exchange transfusion. Acta Paediatrica Scandinavica 1970; 59:(6)681–4.

491